Kidney Week 2020 Reimagined: Embargo Policy
ASN is committed to doing everything we can to help our members and the rest of the kidney community care for people with kidney diseases and adjust to this new reality resulting from the COVID-19 pandemic. With the cancellation of some nephrology meetings as well as the transition from live to virtual of other nephrology meetings, ASN has received requests for the Society to accommodate abstracts that were accepted at other nephrology meetings in 2020 to be submitted for consideration at this year's Kidney Week.
For Kidney Week 2020, ASN has updated its standard embargo policy and will consider submissions of research abstracts and clinical case reports that were published and/or presented in 2020.
Please read and adhere to the following embargo policy for ASN Kidney Week abstracts.
- This ASN embargo policy for ASN Kidney Week abstracts (i.e., research abstracts and clinical case reports), oral presentations, and posters supersedes all other embargoes.
- Accepted Kidney Week abstracts, with the exception of late-breaking clinical trials, will be posted online on October 9, 2020. Titles of accepted late-breaking clinical trials will be posted online on October 9, 2020.
- ASN will not accept an abstract submission if the abstract:
- has been published prior to January 1, 2020, or
- has been presented (oral or poster) at another meeting or press conference prior to January 1, 2020.
- Any information beyond what is contained in the four corners of the abstract may not be released until ASN lifts the embargo. With permission of the authors, ASN may selectively lift the embargo prior to presentation at Kidney Week to coincide with ASN Kidney Week press briefing schedules or other press promotions.
Late-Breaking Clinical Trials: All accepted late-breaking clinical trial oral presentations and posters are under embargo until time of presentation at the ASN meeting. If this embargo policy is violated, ASN reserves the right to sanction the violator (authors or press).
SEC Fair Disclosure Requirements
In certain cases, a determination may be made that in order to fulfill the requirements of the U.S. Securities and Exchange Commission (SEC) or a corresponding regulatory organization in any country where that company's stock is traded, a publicly traded company, before the public release date, must disclose data or information from confidential abstracts. This is generally deemed necessary when it is considered probable that a reasonable investor in the company would regard such data or information as constituting a significant change to the totality of information provided to the investor.
The abstract generally remains eligible to be included in ASN Kidney Week on the condition that the company, prior to the release, submits a letter to ASN signed by the company's legal counsel. The letter must include the title of the abstract, specify the format/nature of the public disclosure, and inform the reader that the information must be publicly disclosed in order to comply with securities laws and that the information disclosed is the minimum necessary to be in compliance with these laws. ASN requirements further specify that the lead author be copied on the request.
Questions? Please contact ASN Press Officer Christine Feheley at email@example.com.